March 2026 in “JMIR Dermatology” Interest in JAK inhibitors for alopecia areata increased significantly after FDA approval, highlighting the need for patient education.
November 2025 in “Journal of Investigative Dermatology” Certain CD8+ T cells attack hair follicles in alopecia areata, suggesting they could be targeted for treatment.
June 2025 in “Revista Foco” JAK inhibitors effectively treat severe alopecia areata with manageable side effects.
April 2025 in “Journal of Dermatology for Physician Assistants” Vitiligo and alopecia should be covered by Medicaid and TRICARE as medical, not cosmetic, conditions.
January 2025 in “bioRxiv (Cold Spring Harbor Laboratory)” Potential therapeutic targets for scarring hair loss are identified.
September 2023 in “Pharmaceuticals” Tiny particles improved delivery of hair loss treatments to hair follicles, with lipid-based particles performing best.
July 2023 in “Journal of the European Academy of Dermatology and Venereology” Hair loss can indicate various health issues, including serious diseases, hormonal imbalances, and can significantly affect personal life and mental health.
Modern skin cancer treatments can cause skin side effects and hair loss, affecting patients' quality of life.
October 2022 in “The American journal of gastroenterology” Thymoma-associated multiorgan autoimmunity can cause liver damage and affects multiple organs, with limited treatment options and a generally poor prognosis.
June 2026 in “Wiener klinische Wochenschrift” New treatments for alopecia areata show promise but need ongoing use and have infection risks.
January 2026 in “Medicina” JAK inhibitors show promise for treating various skin disorders effectively and safely.
May 2025 in “Clinical Proteomics” Key proteins and potential drugs for treating alopecia areata were identified.
January 2025 in “Indian Dermatology Online Journal” Early diagnosis and aggressive treatment are essential for managing Vogt-Koyanagi-Harada syndrome effectively.
144 citations
,
November 2020 in “Frontiers in immunology” Targeting the IL-23/IL-17 pathway effectively treats several inflammatory skin diseases.
143 citations
,
January 2004 in “Journal of Investigative Dermatology Symposium Proceedings” Alopecia areata is an autoimmune disease causing hair loss, treatable with immune-modulating drugs, and linked to genetics.
63 citations
,
July 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” JAK inhibitors can effectively reverse hair loss in people with alopecia areata.
50 citations
,
March 2021 in “Annals of Translational Medicine” More research is needed to understand and treat morphea effectively.
48 citations
,
April 2021 in “Journal of the American Academy of Dermatology” Topical corticosteroids are the best initial treatment for children's alopecia areata.
45 citations
,
May 2024 in “International Journal of Molecular Sciences” Alopecia areata is caused by immune attacks on hair follicles, affecting hair growth and quality of life.
32 citations
,
January 2012 in “Clinical & Developmental Immunology” Targeting CD200 could be a new treatment for rheumatoid arthritis.
30 citations
,
February 2023 in “Journal of Investigative Dermatology” OX40-targeted therapies may help treat skin diseases by reducing inflammation and balancing immune responses.
28 citations
,
March 2013 in “Journal of Investigative Dermatology” Kv1.3 blockers may help treat alopecia areata and promote hair regrowth.
15 citations
,
January 2020 in “Experimental Dermatology” The document concludes that understanding and treatments for alopecia areata have significantly advanced, now recognizing it as an autoimmune disorder.
10 citations
,
January 2019 in “International Immunology” Immune cells help keep skin healthy and repair it, but imbalance can cause disease.
7 citations
,
June 2024 in “iScience” Androgens increase cervical cancer risk and affect its development.
5 citations
,
May 2024 in “Journal of Allergy and Clinical Immunology Global” Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.
5 citations
,
September 2021 in “Clinical case reports” GLPLS is a rare skin condition with specific hair loss and skin symptoms.
4 citations
,
November 2022 in “Frontiers in Immunology” Lung and liver macrophages protect our tissues and their dysfunction can cause various diseases.
3 citations
,
April 2022 in “Biomolecules” Higher miR-34a levels and the A variant of the MIR-34A gene are linked to increased risk and severity of alopecia areata.
2 citations
,
July 2022 in “Frontiers in Medicine” The cause of Frontal fibrosing alopecia, a type of hair loss, is complex, likely involving immune responses and genetics, but is not fully understood.